The labeling provided to health professionals (but not to the general public) may contain the following additional indications.
(a) For products containing cyclizine hydrochloride, dimenhydrinate, and diphenhydramine hydrochloride identified in Sec. 336.10 (a), (b), and (c). ``For the treatment of vertigo of motion sickness.''
(b) For products containing meclizine hydrochloride identified in Sec. 336.10(d). ``For the treatment of vertigo.''